Biohaven Ltd. (BHVN)

Biohaven's stock price has been impacted by several key events in the past six months. In August 2025, the stock rose after the FDA dropped an advisory committee plan for troriluzole. In September 2025, UBS lowered its price target on Biohaven Pharmaceutical Holding to $26.00 from $27.00. In July 2025, the stock hit a fresh 52-week low of $13.74. In April 2025, Biohaven withdrew its marketing application for troriluzole from the European Medicines Agency (EMA), leading to a 15% drop in stock price. In May 2025, Biohaven reported its first-quarter 2025 financial results and enrolled its first patient into a Phase 2/3 trial in early Parkinson's Disease.

Information regarding specific demand seasonality for Biohaven Ltd.'s products and services was not explicitly found. Demand for its products would typically be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access rather than seasonal patterns.

Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing life-changing treatments in neuroscience, immunology, and oncology. Biohaven's mission is to leverage scientific advancements to create medicines addressing unmet medical needs. The company's pipeline includes drug candidates, encompassing small molecules and biologics. Biohaven is advancing a new portfolio, including troriluzole for Spinocerebellar Ataxia (SCA), Obsessive-Compulsive Disorder (OCD), and Alzheimer's and Parkinson's disease; taldefgrobep alfa for neuromuscular and metabolic diseases; BHV-7000 for epilepsy and mood disorders; MoDE™ and TRAP™ extracellular protein degradation platforms for immunological diseases; BHV-2100 for migraine and neuropathic pain disorders; BHV-8000 for Parkinson's disease and neuroinflammatory disorders; antibody drug conjugates (ADCs) for advanced or metastatic epithelial tumors and urothelial cancer; and other preclinical programs.

Biohaven Ltd. is a global biopharmaceutical company headquartered in New Haven, Connecticut, United States. The company's strategic partnerships indicate a global outlook for its therapies.

Biohaven has established a reputation as a leader in scientific innovation, particularly in transforming migraine treatment. Events impacting Biohaven's reputation have been tied to its stock performance and regulatory news. The withdrawal of the troriluzole marketing application from the EMA in April 2025 likely had a negative impact, while positive developments such as the FDA dropping an advisory committee plan for troriluzole in August 2025 contribute positively.

Biohaven Ltd. has a consensus rating of "Strong Buy" from analysts, with an average price target indicating significant upside potential. This suggests substantial institutional and potentially individual investor interest.